Avalo Therapeutics appoints Kevin Lind to Board effective Oct 1; Dr. Almenoff resigns

Avalo Therapeutics, Inc.

Kevin Lind appointed to Board effective Oct 1, 2025; will serve on Audit Committee and receive option for 40,200 shares vesting over 3 years.
Lind previously led Longboard Pharmaceuticals to $2.6B acquisition by Lundbeck in 2024; was EVP/CFO at Arena Pharmaceuticals.
June Almenoff resigns as director effective Oct 1; her equity awards modified to vest fully and options extended to Sept 30, 2026.
Company advancing Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa; topline data expected mid-2026.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.